Increases in Coronary Sinus Atrial Natriuretic Peptide and Lactate Levels during Angioplasty

1992 ◽  
Vol 82 (s26) ◽  
pp. 37P-37P
Author(s):  
JS Gill ◽  
JT Stewart ◽  
J Mazurkiewicz ◽  
CP Pumphrey ◽  
D Redwood ◽  
...  
1998 ◽  
Vol 95 (5) ◽  
pp. 547-555 ◽  
Author(s):  
J. G. LAINCHBURY ◽  
M. G. NICHOLLS ◽  
E. A. ESPINER ◽  
H. IKRAM ◽  
T. G. YANDLE ◽  
...  

1.The cardiac natriuretic peptides, atrial natriuretic peptide and brain natriuretic peptide, are degraded via clearance receptors and the enzyme neutral endopeptidase (EC 3.4.24.11). We studied the regional plasma concentrations of these peptides and their response to acute neutral endopeptidase inhibition in a consecutive series of patients with a broad spectrum of severity of cardiac dysfunction who were undergoing diagnostic right and left heart catheterization (24 patients, mean age 62.6 years). 2.Baseline blood samples were obtained for hormone analysis from femoral artery, femoral vein, renal vein, hepatic vein, superior vena cava, coronary sinus and pulmonary artery, and initial haemodynamic measurements were made. Twelve patients then received a neutral endopeptidase inhibitor (SCH 32615, 200 ;mg intravenously) and 12 received vehicle alone. The cardiac catheterization procedure was then completed and haemodynamic and hormone measurements were repeated. 3.Haemodynamic status was similar at baseline in both groups, and at repeated measurement (post-procedure after placebo or active drugs) haemodynamic variables were not significantly different from baseline values. Plasma levels of atrial and brain natriuretic peptides exhibited an arteriovenous increment (344% and 124% respectively) across the heart (femoral artery to coronary sinus) and decrement (by 28–54% and 9–16% respectively) across all other tissue beds (P< 0.05 for all) except the lung (no change). Final levels of atrial natriuretic peptide rose above initial levels at all sites in both groups (P< 0.05) except coronary sinus levels in the vehicle group (no change). The increase was consistently greater in the inhibitor group at all sites (P< 0.05 versus placebo). Levels of brain natriuretic peptide rose at all sites in the inhibitor group only (P< 0.05). The transcardiac step-up in atrial natriuretic peptide was markedly augmented after the administration of neutral endopeptidase inhibitor. Other tissue gradients were not significantly altered by neutral endopeptidase inhibitor. 4.Atrial and brain natriuretic peptides in plasma are degraded by a number of tissues, and respond differently to cardiac catheterization. Neutral endopeptidase has a significant role in determining plasma levels of natriuretic peptides, in part perhaps by influencing the amount of intact peptide reaching the circulation after secretion from the heart.


1985 ◽  
Vol 63 (6) ◽  
pp. 739-742 ◽  
Author(s):  
J. R. Ledsome ◽  
N. Wilson ◽  
C. A. Courneya ◽  
A. J. Rankin

A heterologous radioimmunoassay was used to measure the concentration of immunoreactive atrial natriuretic peptide (iANP) in plasma from the femoral artery of eight chloralose anaesthetized dogs. Mitral obstruction which increased left atrial pressure by 11 cmH2O increased plasma iANP from 97 ± 10.3 (mean ± SE) to 135 ± 14.3 pg/mL. Pulmonary vein distension increased heart rate but did not increase plasma iANP. Bilateral cervical vagotomy and administration of atenolol (2 mg/kg) did not prevent the increase in iANP with mitral obstruction. Samples of blood from the coronary sinus had plasma iANP significantly higher than simultaneous samples from the femoral artery confirming the cardiac origin of the iANP. Release of iANP depends on direct stretch of the atrium rather than on a reflex involving left atrial receptors.


1988 ◽  
Vol 62 (1) ◽  
pp. 56-58 ◽  
Author(s):  
Yasunobu Hirata ◽  
Takashi Serizawa ◽  
Osami Kohmoto ◽  
Tokuichiro Sugimoto ◽  
Hiroaki Matsuoka ◽  
...  

1989 ◽  
Vol 120 (2) ◽  
pp. 170-174 ◽  
Author(s):  
Takashi Masuda ◽  
Masayoshi Shichiri ◽  
Fumiaki Marumo

Abstract. To clarify the degradation of atrial natriuretic peptide (ANP) in dogs, plasma ANP concentrations in blood samples drawn from the coronary sinus, and in simultaneously collected blood samples of the arteries and veins of the lung, liver, kidney, spleen and cervix, and of the supramesenteric artery and the portal vein, were measured, both when infused with exogenous ANP (280 ng · kg−1 · min−1, N= 7) and when not infused (N = 6). Venous ANP concentrations in most organs showed lower values than arterial levels by 11.6 to 33.6%, suggesting degradation during circulation. Exogenous ANP infusion resulted in a 26.0 to 41.9% arterio-venous decrease in ANP levels. These findings suggest that each organ contributes to ANP degradation, and that no specific organ plays a key role. The plasma ANP concentration was not reduced when blood samples were incubated for 60 min at 37°C. The plasma from the coronary sinus and forearm vein contained essentially idential ANP molecular forms, as shown by gel permeation chromatography. Thus, the blood circulation through various organs does not cause high molecular weight ANP to be changed to other forms.


1988 ◽  
Vol 254 (4) ◽  
pp. R607-R610 ◽  
Author(s):  
K. P. Walsh ◽  
T. D. Williams ◽  
C. Spiteri ◽  
E. Pitts ◽  
S. L. Lightman ◽  
...  

To investigate whether atrial natriuretic peptide (ANP) release during paroxysmal tachycardia is due to increased atrial rate or increased atrial pressure, plasma ANP concentrations were measured during atrial pacing at increasing rates in six alpha-chloralose-anesthetized dogs whose atrial pressures were maintained artificially low by balloon occlusion of the inferior vena cava (IVC). These ANP concentrations were compared with those seen during identical increasing atrial rates in the same dogs without IVC occlusion. During incremental pacing without IVC occlusion, pulmonary wedge pressure (PWP; mean +/- SE) rose progressively from 5.3 +/- 1.6 at 200 to 20.2 +/- 2.3 mmHg at 350 beats/min (P less than 0.01), and right atrial pressure (RAP) rose progressively from 2.5 +/- 0.9 at 200 to 6.7 +/- 2.1 mmHg at 350 beats/min (P less than 0.05). At the same time, arterial and coronary sinus ANP concentrations rose from 116 +/- 55 and 339 +/- 91 to 1,126 +/- 226 and 1,960 +/- 456 pmol/l, respectively (P less than 0.01). In contrast, incremental pacing with IVC occlusion produced no significant increase in PWP and RAP. Arterial and coronary sinus ANP concentrations during IVC occlusion were, respectively, 208 +/- 126 and 388 +/- 159 at 200 and 261 +/- 83 and 345 +/- 80 pmol/l at 350 beats/min (NS). This study demonstrates that the release of ANP during tachycardia is primarily dependent on increased atrial pressure and not atrial rate.


2001 ◽  
Vol 120 (5) ◽  
pp. A682-A682
Author(s):  
W GOWERJR ◽  
G CARTER ◽  
C LANDON ◽  
W GOWERIII ◽  
J DIETZ ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document